WHITE PAPER
Controlling Cancer Care: The Expansion of Formulary Exclusions in Oncology
Aug 26, 2022

As national payers have expanded their use of formulary exclusions for Oncology treatments, manufacturers will need to place additional focus on their oncology portfolio’s access strategy. This paper expands upon previous research by incorporating National Comprehensive Cancer Network (NCCN) guidelines and IQVIA’s longitudinal claims data.

Related solutions

Contact Us